|Bid||171.00 x 1200|
|Ask||170.00 x 1000|
|Day's Range||164.62 - 179.00|
|52 Week Range||45.01 - 189.26|
|Beta (5Y Monthly)||1.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||175.58|
Dr. Adrian Burrowes, Family Medicine Phy. & CFP Physicians Group CEO, joined Yahoo Finance to discuss the latest on covid-19.
Manufacturers should focus on producing as many vaccines as possible this year, but the world faces a potential surplus next year in capacity, Moderna's CEO said on Friday. Speaking at a virtual event on vaccine manufacturing, Stephane Bancel said that additional technology transfers might dent their ability to meet production targets. Moderna is on track to make up to 1 billion doses this year and 1.4 billion next year, he said.
Investors in Ocugen (NASDAQ: OCGN) at the start of the year have reason to cheer. The stock has been flying high amid optimism about a deal to co-commercialize a potential coronavirus vaccine in the U.S. Now, the question is whether it's too late to get in on this story -- or if Ocugen's share gains are only just beginning.